ライフサイエンスコーパス: vascular brachytherapy

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 otational atherectomy (0.96 [0.53-1.7]), and vascular brachytherapy (0.60 [0.35-1.0]).

2 e treated with re-DES (58.1%), 132 underwent vascular brachytherapy (23.4%), and 104 were treated wit

3 uting stents, -19.2% (-28.2 to -10.4) versus vascular brachytherapy, -23.4% (-36.2 to -10.8) versus b

4 arget vessel failure was 21.6% (27/125) with vascular brachytherapy and 12.4% (32/259) with the sirol

5 Lesion length was similar between vascular brachytherapy and sirolimus-eluting stent patie

6 een reported to be an abnormal finding after vascular brachytherapy and, possibly, implantation of dr

7 ar follow-up was 14.1% for re-DES, 17.5% for vascular brachytherapy, and 18.0% for conventional ballo

8 sions and a higher prevalence of prior stent/vascular brachytherapy failure than did the rest of the

9 gned to determine the safety and efficacy of vascular brachytherapy for the treatment of diffuse in-s

10 ical and angiographic outcomes compared with vascular brachytherapy for the treatment of restenosis w

11 analysis segment was 29.5% (31/105) for the vascular brachytherapy group and 19.8% (45/227) for the

12 zation was required in 19.2% (24/125) of the vascular brachytherapy group and 8.5% (22/259) of the si

13 rocedural success was 99.2% (124/125) in the vascular brachytherapy group and 97.3% (250/257) in the

14 Compared with the vascular brachytherapy group, minimal lumen diameter was

15 Vascular brachytherapy has demonstrated its efficacy in

16 after treatment of in-stent restenosis with vascular brachytherapy in the Washington Radiation for I

17 Although vascular brachytherapy is the only approved therapy for

18 Vascular brachytherapy (n = 125) or the sirolimus-elutin

19 Vascular brachytherapy of true aorto-ostial lesions (n =

20 The efficacy of vascular brachytherapy on angiographic and clinical outc

21 g the 3 groups; however, patients undergoing vascular brachytherapy presented with more complex lesio

22 hould become a standard analysis site in all vascular brachytherapy trials.

23 Vascular brachytherapy using pure beta-emitter 32P deliv

24 h subsequent recurrence rates are high, with vascular brachytherapy (VBT) affording the best results.

25 the introduction of two major advances, the vascular brachytherapy (VBT) and the drug-eluting stents

26 Late total occlusion after vascular brachytherapy (VBT) continues to be a serious c

27 We analyzed the effects of vascular brachytherapy (VBT) on ostial in-stent restenos

28 Vascular brachytherapy with 192Ir is safe and reduces th

29 Vascular brachytherapy with either gamma or beta sources

30 Vascular brachytherapy with this device causes increased

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。